FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:634-636 August 12, 2004 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Jamieson, C. H.M. PubMed Citation

Chronic myelogenous leukemia (CML) begins as an indolent disease in which the myeloid lineages in the bone marrow and blood gradually expand. Untreated, this chronic phase of CML inexorably progresses to an accelerated phase and finally to a blast crisis, in which large numbers of blast cells appear in the bone marrow and blood. The hallmark of CML is the Philadelphia chromosome, which corresponds to a t(9;22) translocation in which sequences of BCR that encode the N-terminal region of the BCR protein fuse with the tyrosine kinase catalytic domain of the ABL oncogene. This chimeric gene (BCR-ABL) is central . . . [Full Text of this Article]

Source Information

From the Departments of Medicine and Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor.

This article has been cited by other articles:

• Zauli, G., Secchiero, P. (2005). The long and winding road may be getting shorter. Blood 105: 4160-4160 [Full Text]